Case-Based Roundtable Meetings Spotlight: July 2, 2022

During a Targeted Oncology case-based roundtable event, Dipenkumar Modi, MD, and participants discussed the leading later-line therapy options for patients with diffuse large B-cell lymphoma.

At a live virtual event, Devika Das, MD, discussed the use of immunotherapy for patients with extensive stage-small cell lung cancer (ES-SCLC) and for patients with non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Hana F. Safah, MD, discussed risk factors for acute graft-versus-host disease and data supporting treatment for steroid-refractory disease.

During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the approved frontline regimens for patients with advanced clear cell renal cell carcinoma.

During separate virtual live events, Sandy T. Liu, MD, and Moshe Ornstein, MD, MA, discussed what treatment they would choose for a patient with clear cell renal cell carcinoma and the trial data available in this setting.

During a Targeted Oncology case-based roundtable event, Sheela Tejwani, MD, discussed therapy options for a patient with metastatic castration-sensitive prostate cancer.

During a Targeted Oncology case-based roundtable event, Matthew Powell, MD, discussed trials supporting the use of the PARP inhibitors niraparib and olaparib for patients with BRCA-positive ovarian cancer.

During a Targeted Oncology case-based roundtable event, Rana R. McKay, MD, discussed the case of a patient who progressed following treatment with axitinib and pembrolizumab for clear cell renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Mohamed K. Mohamed, MD, PhD, discussed with participants the challenges of treating extensive-stage small cell lung cancer and their views of the CASPIAN and IMpower 133 trial results.

During a Targeted Oncology case-based roundtable discussion, Mehdi H. Hamadani, MD, discussed systemic therapy options for relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Larry D. Anderson, MD, PhD, discussed the results of the DREAMM-2 trial and management of belantamab mafodotin for patients with multiple myeloma.